Could Acasti Pharma Inc Go Up After Reaching All-Time Low?

 Could Acasti Pharma Inc Go Up After Reaching All Time Low?

The stock of Acasti Pharma Inc (CVE:ACST) reached all time low today, Nov, 24 and still has $1.57 target or 5.00% below today’s $1.65 share price. This indicates more downside for the $16.66 million company. This technical setup was reported by If the $1.57 PT is reached, the company will be worth $833,000 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock last traded at $1.65 per share. It is down 6.00% since October 25, 2016 and is uptrending. It has outperformed by 0.59% the S&P500.

More notable recent Acasti Pharma Inc (CVE:ACST) news were published by: which released: “Acasti Pharma Share Gains Massive in Percentage Terms, Tiny in Dollars” on September 14, 2016, also with their article: “News Acasti Pharma Inc.ACST” published on January 08, 2013, published: “Form 6-K Acasti Pharma Inc. For: Oct 26” on October 26, 2016. More interesting news about Acasti Pharma Inc (CVE:ACST) were released by: and their article: “Acasti Pharma Reports Second Quarter 2017 Financial Results” published on October 11, 2016 as well as‘s news article titled: “Acasti Announces 1-for-10 Reverse Stock Split” with publication date: September 29, 2015.

Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $16.66 million. The Firm is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. It currently has negative earnings. The Firm is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment